Citius Oncology secures partial deferral of milestone payment to Dr. Reddy's without penalty

CITIUS ONCOLOGY, INC.

Milestone payment triggered by FDA approval of LYMPHIR was due Sept 9, 2024; partial deferral granted without penalty.
All other terms and conditions of the Asset Purchase Agreement remain in full force and effect.
Further discussions with Dr. Reddy's pending; partial deferral avoids immediate cash outflow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.